Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors | Zendy

Sailing Shi | Zendy; Shengqing Gu | Zendy; Tong Han | Zendy; Wubing Zhang | Zendy; Lei Huang | Zendy; Ziyi Li | Zendy; Deng Pan | Zendy; Jingxin Fu | Zendy; Jun Ge | Zendy; Myles Brown | Zendy; Peng Zhang | Zendy; Peng Jiang | Zendy; Kai W. Wucherpfennig | Zendy; X. Shirley Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Author(s) -

Sailing Shi,

Shengqing Gu,

Tong Han,

Wubing Zhang,

Lei Huang,

Ziyi Li,

Deng Pan,

Jingxin Fu,

Jun Ge,

Myles Brown,

Peng Zhang,

Peng Jiang,

Kai W. Wucherpfennig,

X. Shirley Liu

Publication year - 2020

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-20-0778

Subject(s) - swainsonine , immune system , cancer research , immune checkpoint , biology , in vivo , immunotherapy , cancer cell , cancer , t cell , immunology , cytotoxic t cell , in vitro , biochemistry , genetics , microbiology and biotechnology

Immune checkpoint blockade has shown remarkable efficacy, but in only a minority of patients with cancer, suggesting the need to develop additional treatment strategies. Aberrant glycosylation in tumors, resulting from the dysregulated expression of key enzymes in glycan biosynthesis, modulates the immune response. However, the role of glycan biosynthesis enzymes in antitumor immunity is poorly understood. We aimed to study the immunomodulatory effects of these enzymes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research